Follow-The-Filings

Security · featured owners

ENTA

Enanta Pharmaceuticals Inc. COM Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 15.9%
  • $79M
  • 1 reduce

Who owns this now

Largest portfolio weights among featured holders · max 15.9% (Michael Krensavage - Kren...) · not free-float ownership

  1. Michael Krensavage 15.9%
  2. James Silverman 0.2%
  3. Farallon Capital Management reduce 0.2%

holders

sorted by % of portfolio · long equity only · open a manager for their book

history
Michael Krensavage - Krensavage Asset Management 2026 Q2 15.9% Hold 2,866,138 $42M hist
James Silverman - Opaleye Management 2026 Q2 0.2% Hold 125,000 $2M hist
Farallon Capital Management 2026 Q2 0.2% Reduce −15.8% 2,418,202 $35M hist

3 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $79.2M $67.64M $65.32M
Gross profit — — —
Gross margin — — —
Net income -$133.82M -$116.04M -$81.89M
Net margin * -169.0% -171.6% -125.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $422.79M $299.85M $204.34M
Total non-current assets * $39.48M $76.8M $76.4M
Total assets $462.28M $376.65M $280.73M
Total current liabilities $62.79M $57.54M $48.56M
Total non-current liabilities * $182.75M $190.3M $167.46M
Total equity $216.74M $128.81M $64.72M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$103.15M -$78.76M -$19.27M
Cash from investing -$53.58M $58.24M $40.35M
Cash from financing $198.13M -$27.63M -$26.62M
Net change in cash $41.39M -$48.16M -$5.54M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders